The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare.The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.Presently, a variety of other such chemical entities and molecular glues are under investigation.In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:Type of payment of licensing agreementsUpfront paymentsMilestone payments Type of protein degraderDegronimidsPROTACsSARDs / SERDsSpecific BET and DUB inhibitorsOther protein degraders Therapeutic areaNeurodegenerative disordersOncological disordersOther therapeutic areas Route of administrationOralIntravenousOther routes Key geographical regionNorth AmericaEuropeAsia-Pacific The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:ArvinasCaptor TherapeuticsCelgeneGenetechKymera TherapeuticsMission TherapeuticsProgenraRadius HealthSanofi GenzymeZenopharm Table of Contents  Preface Executive Summary Introduction Current Market Landscape Company Profiles Clinical Trial Analysis KOL Analysis Publication Analysis Funding and Investment Analysis Partnerships and Collaborations Market Sizing and Opportunity Analysis Executive Insights  Concluding Remarks  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]  
Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link Key Market InsightsMore than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development effortsThe pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routesAlthough start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domainClose to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of developmentA number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development effortsPublished scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACsForeseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companiesShort term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needsAs multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions For more information please visit:https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Table of Contents  PREFACE1.1.Selective Hormone Receptor Degraders (SHRDs)3.8.2.Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline4.2.1.KOL Profile (Edward O’Mara)  PUBLICATION ANALYSIS8.1.Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurodegenerative Disorders, 2020-203011.3.4.2.
To order this detailed 485+ page report, please visit this link Key InclusionsA detailed assessment of the current market landscape, providing information on drug developer(s) (year of establishment, headquarters and size of the company), phase of development (marketed, clinical, preclinical, and discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of therapy (monotherapy and combination therapy), type of synlet target, target patient segment, key therapeutic area(s), target indication(s), and route of administration.In addition, the chapter includes a list of screening platforms that are being used by industry players to study synlet interactions between gene pairs.Detailed profiles of large players that are engaged in the development of synthetic lethality-based drugs (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed profiles of their respective lead drug candidates, and an informed future outlook.In addition, the chapter includes tabulated profiles of small-sized and mid-sized players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as location of headquarters, year of establishment, number of employees, and key members of the executive team), recent developments, along with descriptions of their synthetic lethality-based drug candidates.An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, posted during the period 2010-2019 (till May), highlighting the historical trend of tweets, most prolific contributors, frequently discussed synlet targets, popular disease indications and a multivariate tweet benchmark analysis.An analysis of close to 700 peer-reviewed scientific articles related to synthetic lethality, published during the period 2017-2019 (till May), highlighting the research focus within this niche industry segment.It includes an informed opinion on the key trends observed across the aforementioned publications, including information on target disease indications, synlet targets, and analysis based on various relevant parameters, such as study type (review article, research article and case report), research objective, year of publication, key research hubs, most popular authors, provision of grant support, and most popular journals (in terms of number of articles published in the given time period and journal impact factor).An analysis of various abstracts presented at the American Society of Clinical Oncology (ASCO) in the time period 2013-2019 (till May), highlighting several parameters, such as year of (abstract) publication, popular drugs, synlet targets, target cancer indications, popular authors, author designations, industry type (industry and academia) and most active organizations (in terms of number of published abstracts).In addition, this analysis features a multi-dimensional bubble chart analysis to assess the relative level of expertise of the key authors / researchers based on the number of publications, citation count and research gate score.An in-depth analysis of close to 750 grants that have been awarded to research institutes engaged in projects related to synthetic lethality, between 2014 and 2019 (till May), highlighting various important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers.It also features a detailed analysis on most popular synlet targets and target indications, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, grant type, number of synlet targets and number of indications under study.An analysis of the investments made into companies that have proprietary synthetic lethality-based drugs / screening platforms, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.An in-depth benchmark analysis of over 230 synlet targets identified from various credible sources (research publications, government fundings, clinical studies, recent news / tweets and abstracts presented in global conferences), highlighting targets that have already been validated in clinical studies, preclinical studies and early-stage research (cases where there is no lead (therapeutic) candidate being investigated).
Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.Roots Analysis is pleased to announce the publication of its recent study, titled, “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”.The  report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade.The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.In addition to other elements, the study includes:A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of molecule, type of therapy, type of synlet target, target patient segment, key therapeutic area(s), target indication(s), and route of administration.In addition, the chapter includes a list of screening platforms that are being used by industry players to study synlet interactions between gene pairs.Detailed profiles of players that are engaged in the development of synthetic lethality-based drugs, featuring a brief overview of the company, its financial information (if available), detailed profiles of their respective lead drug candidates, and an informed future outlook.An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, posted during the period 2010-2019 (till May), highlighting the historical trend of tweets, most prolific contributors, frequently discussed synlet targets, popular disease indications and a multivariate tweet benchmark analysis.An analysis of close to 700 peer-reviewed scientific articles related to synthetic lethality, published during the period 2017-2019 (till May), highlighting the research focus within this niche industry segment.An analysis of various abstracts presented at the American Society of Clinical Oncology (ASCO) in the time period 2013-2019 (till May), highlighting several parameters, such as year of (abstract) publication, popular drugs, synlet targets, target cancer indications, popular authors, author designations, industry type (industry and academia) and most active organizations (in terms of number of published abstracts).An in-depth analysis of close to 750 grants that have been awarded to research institutes engaged in projects related to synthetic lethality, between 2014 and 2019 (till May), highlighting various important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers.An analysis of the investments made into companies that have proprietary synthetic lethality-based drugs / screening platforms, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.An in-depth benchmark analysis of over 230 synlet targets identified from various credible sources (research publications, government fundings, clinical studies, recent news / tweets and abstracts presented in global conferences), highlighting targets that have already been validated in clinical studies, preclinical studies and early-stage research (cases where there is no lead (therapeutic) candidate being investigated).
(King Abdullah University of Science & Technology (KAUST)) An electrochemical method for stabilizing a reactive molecule can help the development of higher efficiency solar cells.
8
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare.The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.Presently, a variety of other such chemical entities and molecular glues are under investigation.In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:Type of payment of licensing agreementsUpfront paymentsMilestone payments Type of protein degraderDegronimidsPROTACsSARDs / SERDsSpecific BET and DUB inhibitorsOther protein degraders Therapeutic areaNeurodegenerative disordersOncological disordersOther therapeutic areas Route of administrationOralIntravenousOther routes Key geographical regionNorth AmericaEuropeAsia-Pacific The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:ArvinasCaptor TherapeuticsCelgeneGenetechKymera TherapeuticsMission TherapeuticsProgenraRadius HealthSanofi GenzymeZenopharm Table of Contents  Preface Executive Summary Introduction Current Market Landscape Company Profiles Clinical Trial Analysis KOL Analysis Publication Analysis Funding and Investment Analysis Partnerships and Collaborations Market Sizing and Opportunity Analysis Executive Insights  Concluding Remarks  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]  
1
Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link Key Market InsightsMore than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development effortsThe pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routesAlthough start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domainClose to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of developmentA number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development effortsPublished scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACsForeseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companiesShort term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needsAs multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions For more information please visit:https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Table of Contents  PREFACE1.1.Selective Hormone Receptor Degraders (SHRDs)3.8.2.Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline4.2.1.KOL Profile (Edward O’Mara)  PUBLICATION ANALYSIS8.1.Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurodegenerative Disorders, 2020-203011.3.4.2.
Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.Roots Analysis is pleased to announce the publication of its recent study, titled, “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”.The  report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade.The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.In addition to other elements, the study includes:A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of molecule, type of therapy, type of synlet target, target patient segment, key therapeutic area(s), target indication(s), and route of administration.In addition, the chapter includes a list of screening platforms that are being used by industry players to study synlet interactions between gene pairs.Detailed profiles of players that are engaged in the development of synthetic lethality-based drugs, featuring a brief overview of the company, its financial information (if available), detailed profiles of their respective lead drug candidates, and an informed future outlook.An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, posted during the period 2010-2019 (till May), highlighting the historical trend of tweets, most prolific contributors, frequently discussed synlet targets, popular disease indications and a multivariate tweet benchmark analysis.An analysis of close to 700 peer-reviewed scientific articles related to synthetic lethality, published during the period 2017-2019 (till May), highlighting the research focus within this niche industry segment.An analysis of various abstracts presented at the American Society of Clinical Oncology (ASCO) in the time period 2013-2019 (till May), highlighting several parameters, such as year of (abstract) publication, popular drugs, synlet targets, target cancer indications, popular authors, author designations, industry type (industry and academia) and most active organizations (in terms of number of published abstracts).An in-depth analysis of close to 750 grants that have been awarded to research institutes engaged in projects related to synthetic lethality, between 2014 and 2019 (till May), highlighting various important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers.An analysis of the investments made into companies that have proprietary synthetic lethality-based drugs / screening platforms, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.An in-depth benchmark analysis of over 230 synlet targets identified from various credible sources (research publications, government fundings, clinical studies, recent news / tweets and abstracts presented in global conferences), highlighting targets that have already been validated in clinical studies, preclinical studies and early-stage research (cases where there is no lead (therapeutic) candidate being investigated).
1
PEGylated Drugs Market is expected to register a CAGR of 5.53% to reach USD 13,503.67 Million by 2025.PEGylation refers to the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules (proteins, peptides, enzymes, antibody fragments, oligonucleotides, etc.).It is a promising technique to increase the therapeutic efficacy of medicines in clinical settings.Dapirolizumab pegol is an anti-CD40L pegylated Fab and is in Phase 2b of the clinical trial.The drug is being developed for the treatment of systemic lupus erythematosus.Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8436 However, adverse reactions associated with PEGylated drugs and drug recalls are anticipated to restrain the growth of the global PEGylated drugs market during the forecast period.Market DynamicsThe Global PEGylated Drugs Market is emerging due to the increase in the prevalence of chronic diseases such as cancer, growing pharmaceutical industry, and advancements in the biologics sector.For instance, according to the National Cancer Institute, in 2016, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care in the US.The use of advanced drug delivery system with PEGylation technology is significant in the field of anti-cancer therapy as PEGylating enhances retention time of therapeutics which in turn is expected to boost the growth of the global PEGylated drugs market.SegmentationThe Global PEGylated Drugs Market has been segmented into molecule, indication, and region.On the basis of molecule, the global PEGylated drugs market has been segmented into protein, enzyme, aptamer, antigen-binding fragment (FAB’ fragment) and others.
 To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link Key InclusionsA detailed review of the overall landscape of companies developing RNAi therapeutics, including information on phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, target disease indication(s), key therapeutic areas (oncological disorders, infectious diseases, genetic disorders, ophthalmic diseases, respiratory disorders, hepatic disorders, metabolic disorders, cardiovascular disorders, dermatological disorders, and others), type of RNAi molecule (siRNA, miRNA, shRNA, sshRNA and DNA), target genes, type of delivery system used, route of administration and special drug designations (if any).A competitiveness analysis of key players engaged in this domain, evaluating their respective product portfolios, type of RNAi molecule, target therapeutic areas, company size and year of establishment.An analysis of completed, ongoing and planned clinical studies for different types of RNAi molecules.The trials were analyzed on the basis of various relevant parameters, such as registration year, current status, phase of development, type of RNAi molecule, regional distribution of clinical trials and enrolled patient population.An in-depth analysis of the various patents that have been filed / granted related to RNAi therapeutics, since 2014.The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC symbols, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.An analysis of the various partnerships pertaining to RNAi therapeutics, which have been established till August 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, therapeutic area, type of RNAi molecule, financial details (wherever applicable), focus area of collaboration and most active players.An analysis of the investments made at various stages of development in companies engaged in this domain, between 2014-2019, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings.An analysis of the key promotional strategies that have been adopted by developers of marketed oligonucleotide therapeutics, namely Defitelio®, Exondys® and Onpattro®.A review of emerging technology platforms and delivery systems that are being used for targeted therapeutic delivery, featuring detailed profiles of technologies.Detailed profiles of drug candidates that are in the advanced stages of development (phase II/III and above), including information on their current development status, mechanism of action, route of administration, affiliated delivery technology, dosage, recent clinical trial results along with information on their respective developers.An elaborate discussion on the use of miRNA as a potential biomarker, along with a list of diagnostic kits that are either available in the market, or likely to be approved in the foreseen future.The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:Key therapeutic areasOncological disordersInfectious diseasesGenetic disordersOphthalmic disordersHepatic disordersRespiratory disorders Type of RNAi moleculesiRNAmiRNAshRNAsshRNADNA Route of administrationSubcutaneousIntravenousIntradermalIntratumoralIntravitrealOralIntramuscular Key geographical regionsNorth AmericaEuropeAsia Pacific and the Rest of the World Leading Players The report features inputs from eminent industry stakeholder(s), according to whom RNAi therapeutics are promising domain of pharmaceutical industry.The report includes detailed transcripts of discussions held with the following expert(s):Amotz Shemi (Chief Executive Officer, Silenseed) To request sample pages, please visit this link Key Questions AnsweredWho are the leading industry players in this market?What are the clinical conditions for which RNAi therapeutics are being developed?Who are the key investors in the RNAi therapeutics market?What kind of commercialization strategies are being adopted by RNAi therapeutics developers?What are the different promotional and reimbursement strategies used for RNAi therapeutics?What are the prevalent R trends related to RNAi therapeutics?What are the various delivery / technology platforms that are being used for the development of RNAi therapeutics?What kind of partnership models are used by stakeholders in this industry?Who are the key service providers in this field of therapeutics?How is the current and future market opportunity likely to be distributed across key market segments?You may also be interested in the following titles: Gene Therapy Market (3rd Edition), 2019-2030Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030 Contact UsGaurav Chaudhary+1 (415) 800 [email protected]
The potential therapeutic applications of RNAi were realized almost immediately after the phenomenon was first described; over the years, developers have gradually progressed their proprietary drug candidates with cautious optimism Roots Analysis is pleased to announce the publication of its recent study, titled, “RNAi Therapeutics Market (2nd Edition), 2019 - 2030: Focus on siRNA, miRNA, shRNA and DNA.” The “RNAi Therapeutics Market (2nd Edition), 2019-2030: Focus On siRNA, miRNA, shRNA and DNA” report features an extensive study of the current market landscape and future opportunities associated with RNAi therapeutics.The study also features a detailed analysis of key drivers and trends within this evolving market.Amongst other elements, the report includes:A detailed assessment of the current market landscape of drug developers engaged in the development of RNAi therapeutics.A competitiveness analysis of key players engaged in this domain, evaluating their respective product portfolios, type of RNAi molecule, target therapeutic areas, company size and year of establishmentA detailed analysis of more than 70 completed, ongoing and planned clinical studies of RNAi therapeutics.A detailed analysis of various patents that have been filed / granted related to RNAi therapeutics, since 2014An analysis of the partnerships that have been established in this domain, in the recent past.An analysis of the investments made at various stages of development in companies engaged in this domain.An analysis of the key promotional strategies that have been adopted by developers of marketed oligonucleotide therapeutics, namely Defitelio®, Exondys® and Onpattro®.Detailed profiles of RNAi Therapeutics that are in the late stage clinical developmentA detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Key Therapeutic AreasOncological disordersInfectious diseasesGenetic disordersOphthalmic disordersHepatic disordersRespiratory disordersType of RNAi moleculesiRNAmiRNAshRNAsshRNADNARoute of administrationSubcutaneousIntravenousIntradermalIntravitrealOralIntramuscularKey geographical regionsNorth AmericaEuropeAsia Pacific and the Rest of the worldLeading Player Key companies covered in the reportQuark PharmaceuticalsAlnylam PharmaceuticalsDicerna PharmaceuticalsSouzhou Ribo Life SciencesOlix PharmaceuticalsSirnaomicsAriz Precision MedicineArrowhead PharmaceuticalsGradalisBenitec Biopharma For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.htmlOther Recent OfferingsGene Therapy Market (3rd Edition), 2019-2030Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]
The newest addition to the rich archive of business intelligence reports of Fact.MR is a study on the Global Small Molecule Injectables market for the forecast tenure of 2020 to 2025.This new study is an all-out effort made by the analysts of Fact.MR to come up with accurate data and information-laden report that addresses the unmet needs of the stakeholders of the Global Generic Injectables market.This report makes an offering of detailed assessment of various important market dynamics, which comprise restraints, opportunities, trends, and drivers of the Global Generic Injectables market.This business intelligence report comes with exclusive information as to how the Global Generic Injectables market can expand during the assessment tenure of 2020 to 2025.The report on the global Generic Injectables market provides an up-to-date analysis of the existing scenario of the market along with the latest drivers and trends, and the overall environment of the said market.Request to View Sample of Research Report @ https://www.factmr.com/connectus/sample?flag=S_id=4681In this report, various key indicators of market growth, such as value chain, CAGR (Compounded Annual Growth Rate), supply chain analysis, and Year-on-Year (Y-o-Y) growth of the market have been elaborately discussed for better comprehension of the market.
1
The global human microbiome therapeutics market size is expected to reach USD 1,544.6 million by 2027 according to a new study by Polaris Market Research.The report “Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, and Prescription Drugs); By Therapeutic Area (Autoimmune Disorders, Dental Disorders, Digestive and Gastrointestinal Disorders, Dermatological Disorders, Infectious Disease, Metabolic Disorders, Oncology, and Others); By Indication (Acne Vulgaris, Atopic Dermatitis, Clostridium difficile Infection, Colorectal Cancer, Diabetes, Inflammatory Bowel Disease (IBD), Lactose Intolerance, Lung Cancer, Non-alcoholic steatohepatitis (NASH), Obesity, and Coeliac Disease); By Approach (Small Molecule Therapies, Single Strain Whole Bacteria, Microbial Consortia, Genetically Modified Single Strain Bacteria, Phage Cocktail, and Microbial Ecosystems), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.Microbiome refers to the residing micro-organisms genomes in the human body, particularly in the gut.The human body comprises more than 100 trillion microbes and around 2 million microbe genomes.The majority of these are strict anaerobes, with fungi and archaebacteria comprising less than 1 per cent of the total population.Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market/request-for-sample The global market is driven by an increased focus on microbiome based early diagnosis of diseases, increase in the prevalence of diseases due to dysbiosis, rising collaborations, and strongly funded government backed microbiome research projects.
1
Oncology Small Molecule Drugs Market: OverviewThe oncology small molecule drugs market is prophesied to display phenomenal growth and outperform other available drug therapies for the treatment of cancer in the forthcoming years.The report delves into each and every important facet that could have an impact on the growth of the market over the forecast period.Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=78172Oncology Small Molecule Drugs Market: Competitive LandscapeThe oncology small molecule drugs market features an intensely competitive vendor landscape.Being a relatively new line of therapeutics for cancer, due to high clinical expertise, and high costs only a few large pharmaceutical companies have presence in the oncology small molecule drugs market.Some top-rated research institutions and clinical laboratories are engaged in intense research to demonstrate the effectiveness of small molecule drugs therapy.BET Small Molecule Inhibitor Discovery by Yale University researchers, AOH1160 Small Molecule Research to focus on breast cancer at University of California are some examples of initiatives for further research in small molecule cancer drugs.Some promising players in the oncology small molecule drugs market areJohnson & Johnson, Boehringer Ingelheim, Pfizer, Merck, GlaxoSmithkline, Gilead Sciences, Teva Pharmaceutical, Allergan, Bristol- Myers Squibb, and AstraZeneca.Request a Sample of Oncology Small Molecule Drugs Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S_id=78172Oncology Small Molecule Drugs Market: Key TrendsAmong a number of cancer treatments that are commercially available, small molecule drugs are associated with several parameters that make them quite promising for use.Owing to being specific and target oriented, small molecule drugs approach has attained interest of stakeholders in the cancer therapy market.This holds immense growth potential for oncology small molecule drugs market.Request for Analysis of COVID19 Impact on Oncology Small Molecule Drugs Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=78172Meanwhile, various cancer studies for various cancer types confirm there are receptors for target that are present inside the cell membrane.
Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers.To order this 375+ page report, which features 180+ figures and 195+ tables, please visit this link The USD 1.7 billion financial opportunity (by 2030) within the ophthalmic drugs contract manufacturing market has been analyzed across the following segments:Type of productOphthalmic APIOphthalmic drug FDF Type of FDF manufacturedSolidSemi-solidLiquid / suspension Type of primary packagingAmpoule / vialGlass / plastic bottleOintment tubeBlister packingOther forms Scale of manufacturingClinicalCommercial Company sizeSmallMid-sizedLargeVery large Target disease indicationAge-related macular degenerationDry eyeGlaucomaOther disease segments Key geographical regionsNorth America (US, Canada and Mexico)Europe (UK, Germany, France, Spain, Italy and rest of Europe)Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)Rest of the world The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030 report features the following companies, which we identified to be key players in this domain: AkornAkumsBal PharmaCatalentCayman ChemicalEntod PharmaceuticalsFarmigeaGlenmark PharmaceuticalsIndiana OphthalmicsLomapharmMedichemPillar5 PharmaRecipharmSalvatSterling Pharmaceutical ServicesSunways India Table of Contents  Preface 2.Executive Summary Introduction Current Market Landscape Company Competitiveness Analysis Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles Clinical Trial Analysis Capacity Analysis Demand Analysis Market Forecast Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies SWOT Analysis  Survey Analysis  Executive Insights  Future Growth Opportunities Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers  Appendix 2: Tabulated Data  Appendix 3: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html Contact:Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 [email protected]
The process of chaining or modification of biological molecules by conjugation with non-immunogenic polymer and nontoxic polyethylene glycol to improve or modify the physicochemical property of molecule is known as PEGylation.PEGylation improves stability and solubility of drug and decreases immunogenicity by changing the electrostatic binding, confirmation, and hydrophobicity of the molecule.PEGylation decreases the dose frequency by reducing renal excretion and proteolysis, and increases tension time of conjugates in blood and stability of drug.Pegaspargase, pegademase bovine, pegfilgrastim, certolizumab pegol, pegvisomant, pegaptanib, and interferons are the most important PEGylated drugs.The consumables segment includes PEGylation kits and reagents.Request for Analysis of COVID19 Impact on PEGylated Proteins Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=18539In terms of application, the PEGylated proteins market can be segmented into hepatitis, hemophilia, cancer, multiple sclerosis, gastrointestinal disorder, and others.The pharmaceutical and biotechnology companies segment is expected to witness fastest growth during the forecast period led by increasing R spending in pharmaceutical and biotechnology sectors globally.Purchase PEGylated Proteins Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=18539=SIn terms of region, the PEGylated proteins market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The production of radiopharmaceuticals as compared to traditional pharmaceuticals is a multifaceted procedure and requires specialized facilities, equipment and operational expertise.Further, owing to its inherent hazardous nature, radiopharmaceuticals have a complex regulatory market authorization process.Consequently, a number of innovator companies have demonstrated a preference for outsourcing radiopharmaceutical manufacturing to contract service providers.To order this 320+ page report, which features 45+ figures and 100+ tables, please visit this link The USD 6+ billion (by 2030) financial opportunity associated with nuclear medicine and radiopharmaceuticals manufacturing, has been analyzed across the following segments:Target Disease Indication Breast CancerChronic Lymphocytic LeukemiaColorectal CancerHead and Neck CancerLung CancerLupus NephritisMelanomaMultiple MyelomaPrimary Sjögren's SyndromeOthers  Target Immune CheckpointB7-H3CD38CD40CD47Others Mechanism of ActionInhibitoryStimulatory Therapeutic ModalityMonoclonal AntibodySmall Molecule Type of Therapy Monotherapy Combination Therapy Route of AdministrationIntravenousSubcutaneousOthers Key Geographical Regions North AmericaEuropeAsia-Pacific and the Rest of the World  The Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: Advanced Accelerator ApplicationsBelgian Nuclear Research Center (SCK•CEN)Cardinal HealthChina Isotope & Radiation CorporationCurium PharmaDuChemBioEckert & ZieglerEczacibasi-MonrolGE HealthcareJubilant DraxImageLantheus Medical ImagingNihon Medi-PhysicsNordionPETNET SolutionsSinoTau PharmaceuticalsSOFIE Table of Contents  Preface 2.Executive Summary Introduction Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Current Market Landscape Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Current Market Landscape Nuclear Medicine and Radiopharmaceuticals Manufacturers in North America Nuclear Medicine and Radiopharmaceuticals Manufacturers in Europe Nuclear Medicine and Radiopharmaceuticals Manufacturers in Asia-Pacific And Rest of The World Nuclear Medicine and Radiopharmaceuticals Manufacturers: Company Competitiveness Analysis Partnerships and Collaborations Production and Supply Chain of Medical Isotope Molybdenum-99 (Technetium-99m) Market Forecast and Opportunity Analysis Concluding Remarks  Executive Insights  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]   
1
The global active pharmaceutical ingredient (API) market size is expected to reach USD 306.1 billion by 2027 according to a new study by Polaris Market Research.The report “Active pharmaceutical Ingredient (API) market Share, Size, Trends, Industry Analysis Report, By Product Type (Monoclonal Antibodies, Immunoglobulin, Cytokines, Insulin, Peptide Hormones, Blood Factors, Peptide Antibiotics, Vaccines, Small Molecule Antibiotics, Highly Potent Active Pharmaceutical Ingredient (HPAPI), and Others); By Form (Aqueous, Non-Aqueous Liquid, and Dry Powder); By Manufacturer Type (Captive, and Merchant); By Application (Cardiology, Oncology, CNS & Neurology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, and Others), By Regions; Segment Forecast, 2020 –2027”gives a detailed insight into current market dynamics and provides analysis on future market growth.Active Pharmaceutical Ingredient (API) is a substance involved in the finished pharmaceutical product (FPP), aimed to enhance the pharmacological activity or have direct impact in the cure, mitigation, diagnosis, treatment of disease or in modifying, correcting or restoring physiological functions in the human body.The prominent factors favoring the global market include the sudden outbreak of novel corona virus, which is rapidly escalating the demand for pharmaceuticals and thereby fueling the overall market growth.Additionally, rise in aging population, rising cases of cardiovascular diseases, cancer, AIDs, other infectious diseases, are further contributing to augmenting demand for APIs that are used in drugs.Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/active-pharmaceutical-ingredients-market/request-for-sample Market participants such as AbbVie Inc., Albemarle Corporation, AstraZeneca, Aurobindo Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla Inc., Dr. Reddy’s Laboratories Ltd., ELI Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline PLC, Lonza Group, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer, Inc., Sanofi, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd. are some of the key players operating in the global market.
The global active pharmaceutical ingredient (API) market size is expected to reach USD 306.1 billion by 2027 according to a new study by Polaris Market Research.The report “Active pharmaceutical Ingredient (API) market Share, Size, Trends, Industry Analysis Report, By Product Type (Monoclonal Antibodies, Immunoglobulin, Cytokines, Insulin, Peptide Hormones, Blood Factors, Peptide Antibiotics, Vaccines, Small Molecule Antibiotics, Highly Potent Active Pharmaceutical Ingredient (HPAPI), and Others); By Form (Aqueous, Non-Aqueous Liquid, and Dry Powder); By Manufacturer Type (Captive, and Merchant); By Application (Cardiology, Oncology, CNS & Neurology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, and Others), By Regions; Segment Forecast, 2020 –2027”gives a detailed insight into current market dynamics and provides analysis on future market growth.Active Pharmaceutical Ingredient (API) is a substance involved in the finished pharmaceutical product (FPP), aimed to enhance the pharmacological activity or have direct impact in the cure, mitigation, diagnosis, treatment of disease or in modifying, correcting or restoring physiological functions in the human body.The prominent factors favoring the global market include the sudden outbreak of novel corona virus, which is rapidly escalating the demand for pharmaceuticals and thereby fueling the overall market growth.Additionally, rise in aging population, rising cases of cardiovascular diseases, cancer, AIDs, other infectious diseases, are further contributing to augmenting demand for APIs that are used in drugs.Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/active-pharmaceutical-ingredients-market/request-for-sample Market participants such as AbbVie Inc., Albemarle Corporation, AstraZeneca, Aurobindo Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla Inc., Dr. Reddy’s Laboratories Ltd., ELI Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline PLC, Lonza Group, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer, Inc., Sanofi, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd. are some of the key players operating in the global market.
The vendor landscape of the antiviral drugs market is consolidated with the dominated of few players, says Transparency Market Research (TMR).The market shares of geriatric players in increasing rapidly in the market Some of geriatric players operating in the antiviral drugs market are Aurobindo Pharma, Cipla, and Dr Reddy’s.Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=21083The players in the antiviral drugs market are focusing towards the development of generic version of key blockbuster drugs.This will help the company gain greater cosunmer preference on the virtue of lower costs.Promient players are collaborating with the geriatric players to remain competitive in the global market.For instance, in 2016, Roche announced its plans to take over anti-influenza drug molecule of a key competitor Shionogi after facing heavy generic competition from the star drug Tamiflu.Request a Sample of Antiviral Drugs Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S_id=21083A recently released report by TMR elucidates that the anitiviral drugs market is projected to rise at a CAGR of 6.40% during the forecast period that is from 2016 and 2024.Request for Analysis of COVID19 Impact on Antiviral Drugs Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=21083Bolster Market’s GrowthThe global antiviral drugs market is projected to rise at a significant pace in the coming few years.These has resulted the development of novel therapeutics for antiviral drugs thus bolstering the market’s growth.As per a study,  over 36 million people around the globe are suffering from HIV infection in 2014.
More

Top